Feds enter agreement for 72 million doses of adjuvanted COVID-19 vaccine


Published September 22, 2020 at 9:29 pm


The Government of Canada has entered into agreements with GlaxoSmithKline (GSK) and Sanofi Pasteur for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine.

The vaccine, which reportedly will be available globally at an affordable rate, will become available sometime in 2021.

“This announcement showcases our unwavering commitment to develop a COVID-19 vaccine that is available to everyone when it comes to market,” Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, said in a news release.

“To address a global health crisis of this magnitude, it takes partnerships and we are grateful to Canada for its collaboration, and to GSK for partnering with us to develop a safe and effective vaccine,” he continued.

Both companies’ global manufacturing networks will play a pivotal role in the production of the vaccine, while Sanofi’s Toronto vaccine manufacturing site will play a role in process and analytical development along with clinical manufacturing to support Sanofi Pasteur’s overall global efforts to develop and manufacture a vaccine that protects against the virus.

“Sanofi has a long-standing legacy of developing safe and effective vaccines for Canadians,” Jean-Pierre Baylet, general manager for Sanofi Pasteur Canada, said in the same release.

“The partnership with the Government of Canada marks a key milestone in protecting and serving the Canadian population against COVID-19 and builds on our Toronto manufacturing site’s more than 100-year history as a reliable public health partner,” he continued.

Sanofi is leading the clinical development and registration of the COVID-19 vaccine, and a Phase 1/ 2 study began on September 3 with a total of 440 subjects.

The company anticipates results will be ready by December 2020, after which a pivotal Phase 3 study will begin before the end of the year.

If the data is sufficient for regulatory application, a request for regulatory approval will be made in the first half of 2021.

insauga's Editorial Standards and Policies

Stay the know

Subscribe now to receive our daily email of today's top stories in your city!

Related News